LEADER 03775nam 2200589Ia 450 001 9910437856103321 005 20200520144314.0 010 $a1-299-33578-0 010 $a1-4614-5438-7 024 7 $a10.1007/978-1-4614-5438-0 035 $a(CKB)2670000000326562 035 $a(EBL)1081920 035 $a(OCoLC)827212494 035 $a(SSID)ssj0000879444 035 $a(PQKBManifestationID)11532214 035 $a(PQKBTitleCode)TC0000879444 035 $a(PQKBWorkID)10853021 035 $a(PQKB)11743608 035 $a(DE-He213)978-1-4614-5438-0 035 $a(MiAaPQ)EBC1081920 035 $a(PPN)168303035 035 $a(EXLCZ)992670000000326562 100 $a20130225d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPathobiology of cancer regimen-related toxicities /$fStephen T. Sonis, Dorothy M. Keefe, editors 205 $a1st ed. 2013. 210 $aNew York $cSpringer$d2013 215 $a1 online resource (291 p.) 300 $aDescription based upon print version of record. 311 $a1-4899-9070-4 311 $a1-4614-5437-9 327 $aPreface.-Epidemiology and outcomes of regimen-related toxicities -- The biological basis for differences in normal tissue response to radiation therapy and strategies to establish predictive assays for individual complication risk -- The bystander effect: Ionizing radiation-induced non-targeted effects: Evidence, mechanism and significance -- The role of genes on the metabolism of chemotherapeutic agents and their impact on toxicity.-  Animal models of regimen-related toxicities -- Nausea and Vomiting -- Mucositis -- Dermatitis and Alopecia.-  Fibrosis.-  Myelosuppression -- Neuropathy -- Fatigue -- Xerostomia -- Osteonecrosis -- Conclusions and therapeutic opportunities -- Index. 330 $aToxicities have been consistent undesirable companions of every form of radiation and drug cancer treatment regimens.  In addition to the potential for toxicities to devastate patients? quality of life, they generate huge incremental financial costs, and sap patients? ability to tolerate definitive cancer therapy.   And every new drug or biological has come with new side effects.   Historically, regimen-related toxicities were viewed as the inevitable cost of treating cancer.  But this may be about to change. Discoveries in the past dozen years have painted a new picture of the pathobiology of almost all regimen-related toxicities.  The mechanistic complexities that underlie radiation- and chemotherapy-induced tissue injury or systemic symptoms have been pieced together in an incremental sequence which now provides multiple targets for effective toxicity interventions. This book brings together, for the first time in a single volume, the most current information regarding both general principles guiding current thinking about the pathogenesis of regimen-related toxicities and the specific biological underpinnings of the most common side effects of cancer therapy.  The contents provide information that is essential to clinicians and basic and translational scientists interested in cancer therapy and its toxicities. 606 $aCancer$xChemotherapy$xComplications 606 $aAntineoplastic agents$xToxicology 615 0$aCancer$xChemotherapy$xComplications. 615 0$aAntineoplastic agents$xToxicology. 676 $a616.99 676 $a616.99406 700 $aSonis$b Stephen T$01749892 701 $aKeefe$b Dorothy M$01749893 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437856103321 996 $aPathobiology of cancer regimen-related toxicities$94184356 997 $aUNINA